Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.
OBJECTIVE
Although nonalcoholic fatty liver disease (NAFLD) is very common among morbidly obese patients, the effect of weight loss after bariatric surgery on inflammation and fibrosis related to NAFLD is still a matter of debate. The aim of this study was to evaluate the impact of Roux-en-Y gastric bypass (RYGB) surgery on NAFLD with a follow up of 2 years.


METHODS
Eighteen consecutive NAFLD patients with body mass index >40 kg/m(2) undergoing gastroplasty with RYGB were enrolled, and wedge liver biopsy was obtained at the operation. After 2 years, these patients underwent percutaneous liver biopsy.


RESULTS
At baseline, 67% of patients had nonalcoholic steatohepatitis (NASH) and 33% had steatosis, according to the NASH Clinical Research Network Scoring System (NAS) for biopsy. Cirrhosis was present in 5.5% of the patients with NASH. After a mean excess weight loss of 60%, steatosis disappeared in 84% and fibrosis disappeared in 75% of the patients. Hepatocellular ballooning disappeared in 50%. A slight lobular inflammatory infiltrate remained in 81%, apparently unrelated to fatty degeneration. As liver biochemical variables had been found within normal limits in 92.3% of patients at initial biopsy, no difference was found 2 years later. Lipid profile and blood sugar plasma concentration were closer to normal in all patients after 2 years (P < 0.05).


CONCLUSIONS
Aspects of NAFLD including steatohepatitis improved significantly with massive weight loss at 2 years after RYGB surgery. No patient in this series had progression of hepatic fibrosis.
Furuya
Carlos K
CK
Department of Gastroenterology, Division of Endocrinology, University of São Paulo School of Medicine, São Paulo, Brazil.
de Oliveira
Claudia P M S
CP
de Mello
Evandro S
ES
Faintuch
Joel
J
Raskovski
Alessandra
A
Matsuda
Mitsunori
M
Vezozzo
Denise C P
DC
Halpern
Alfredo
A
Garrido
Arthur B
AB
Alves
Venâncio A F
VA
Carrilho
Flair J
FJ
D000328:Adult; D050110:Bariatric Surgery; D001706:Biopsy; D015992:Body Mass Index; D015897:Comorbidity; D005234:Fatty Liver / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000097:blood; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000150:complications / Q000601:surgery*; D005723:gamma-Glutamyltransferase / Q000097:blood
D008055:Lipids; D005723:gamma-Glutamyltransferase